Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

85 results
Display

Letter: A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67)

Rhee EJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risks associated with sunitinib use and monitoring to improve patient outcomes

Choi BS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Efficacy and Safety of a Tofacitinib in the Treatment of Active Ulcerative Colitis

Seo GS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?

Kwok SK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Sunitinib-Induced Destructive Thyroiditis

Kim BK, Choi YS, Park YH

Sunitinib is a multi-targeted tyrosine-kinase inhibitor used for gastrointestinal stromal tumors and renal cell carcinoma (RCC). Several recent studies have reported sunitinib-induced hypothyroidism and thyroid dysfunction; however, the underlying mechanisms...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case of thyrotoxicosis after sunitinib treatment

Lee HY, Kim MK, Kim NK, Kim HS, Ryu SY, Kwon KY, Park KG

  • KMID: 2259167
  • Korean J Med.
  • 2010 Apr;78(4):503-506.
Sunitinib is a tyrosine-kinase inhibitor used to treat metastatic renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors. Hypothyroidism is a common side effect of sunitinib therapy. Nevertheless, overt thyrotoxicosis induced by...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67)

Kim DK, Lee SR, Kim MS, Bae SH, Hwang JY, Kim JM, Suh SH, Lee HJ, Park MK, Kim DK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patient with Malignant Granular Cell Tumor Treated with Sunitinib Malate

Lee SJ, Kim JH, Cho HW, Na GJ, Kim HJ, Bae SB, Lee KT

  • KMID: 2317687
  • Soonchunhyang Med Sci.
  • 2012 Jun;18(1):66-69.
Malignant granular cell tumors (MGST) are extremely rare, high-grade sarcoma of schwann cell origin. They often metastasize and are associated with short survival. We described a patient with recurred MGST...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Hand-Foot Syndrome with Pustules and Paronychia Induced by Sunitinib

Choi JW, Kim SW, Woo SM, Won CH, Cho S

  • KMID: 2248073
  • Korean J Dermatol.
  • 2008 Oct;46(10):1384-1386.
In January 2006, Sunitinib was approved by the US Food and Drug Administration for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor. Sunitinib inhibits the receptor tyrosine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Hand-Foot Syndrome Induced by Sunitinib

Jeong JS, Yun JH, Yoon SJ, Kim WJ, Lee JY, Yoon TY

  • KMID: 1484230
  • Korean J Dermatol.
  • 2008 Sep;46(9):1236-1239.
Sunitinib (SU11248) is a novel orally administered small molecule that inhibits multiple receptor tyrosine kinases so that can block tumor growth and angiogenesis. It was approved on 2006, for the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sunitinib-induced hypothyroidism

Chung YJ

  • KMID: 1458427
  • Korean J Med.
  • 2010 Nov;79(5):506-508.
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. Currently, sunitinib is being investigated in multiple other tumor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Angiogenic Inhibitor Induced Complicated Reflux Esophagitis

Ryu JI, Jung HK, Cho MS, Lee MJ, Song ME, Oh DY, Song HE

Sunitinib an inhibitor of the vascular endothelial growth factor receptor, is highly effective against renal cell carcinoma and is now widely used in patients with metastatic disease. Gastroesophageal reflux disease...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Assessment of Therapeutic Effect of Sunitinib by 11C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma

Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, Okazawa H, Kudo T, Fujibayashi Y, Yokoyama O

  • KMID: 1447599
  • Nucl Med Mol Imaging.
  • 2011 Sep;45(3):217-219.
Although sunitinib shows a high response rate in patients with untreated metastatic renal cell carcinoma (mRCC), quite a few patients show no therapeutic effect. Therefore, it is crucial to distinguish...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Bullous Fixed Drug Eruption Coexisting with Hand-Foot Syndrome and This Was Induced by Sunitinib

Jeong TJ, Lee EJ, Jeong KH, Shin MK, Kim NI

  • KMID: 2247829
  • Korean J Dermatol.
  • 2009 Jun;47(6):739-742.
Sunitinib is multitargeted tyrosine kinase inhibitor, and this drug was approved for use to treat gastrointestinal stromal tumor and advanced renal cell carcinoma. It has also been shown to be...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, Rha SY

  • KMID: 2270809
  • Cancer Res Treat.
  • 2010 Sep;42(3):180-184.
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gastrointestinal Stromal Tumor

Kim YJ, Kim SS

Gastrointestinal stromal tumor (GIST) is a relatively rare disease accounted for less than 1% of gastrointestinal tumors. In the past, surgery is the only reliable therapy for the locoregional GISTs....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biopsy-Proven Immune Complex Glomerulonephritis Associated with Sunitinib in a Patient with a Gastrointestinal Stromal Tumor

Lee H, Lee HR, Oh KH, Moon KC, Ahn C, Kim S, Bang YJ

  • KMID: 2252987
  • Korean J Nephrol.
  • 2010 Sep;29(5):644-649.
Sunitinib, a multi-targeted tyrosine kinase inhibitor, is used for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Many adverse effects associated with sunitinib, including hypertension, proteinuria, and thrombotic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Treated with Tyrosine Kinase Inhibitor

Kim YH, Kim JE, Park S, Jang TY

Renal cell carcinoma is a rare metastatic malignant neoplasm of the paranasal sinus. The clinical picture and radiologic findings might sometimes be insufficient to suspect metastatic renal cell carcinoma. Therefore,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura

Kim EJ, Choi YM, Lee SW, Ha YJ, Lee JL

  • KMID: 2267896
  • Korean J Med.
  • 2013 Feb;84(2):303-307.
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP-HUS) is an acute condition with abnormalities of multiple organ systems. It is characterized by microangiopathic hemolytic anemia and thrombocytopenia. Several chemotherapeutic agents...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
TTP-HUS Associated with Sunitinib

Choi MK, Hong JY, Jang JH, Lim HY

  • KMID: 1972650
  • Cancer Res Treat.
  • 2008 Dec;40(4):211-213.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Adverse reactions to drugs increasingly are reported as probable causes of TTP-HUS. Many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr